Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

35.99 +1.56 (+4.53%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	111,961
Open	34.66
Bid (Size)	17.92 (200)
Ask (Size)	41.00 (200)
Prev. Close	34.43
Today's Range	34.66 - 36.50
52wk Range	4.500 - 57.14
Shares Outstanding	34,432,122
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Voting Rights and Shares Capital of the Company

June 05, 2026

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

From Nanobiotix S.A.

Via GlobeNewswire

Nanobiotix Provides First Quarter 2026 Operational and Financial Update

June 02, 2026

From Nanobiotix S.A.

Via GlobeNewswire

Performance

YTD	+62.6%	+62.6%
1 Month	-11.8%	-11.8%
3 Month	+14.9%	+14.9%
6 Month	+56.2%	+56.2%
1 Year	+694.5%	+694.5%

More News

Nanobiotix Joins the Euronext Tech Leaders Index

June 02, 2026

From Nanobiotix S.A.

Via GlobeNewswire

NANOBIOTIX Announces Closing of Global Offering

May 26, 2026

From Nanobiotix S.A.

Via GlobeNewswire

NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million

May 22, 2026

From Nanobiotix S.A.

Via GlobeNewswire

Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering

May 21, 2026

From Nanobiotix S.A.

Via GlobeNewswire

Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris

May 21, 2026

From Nanobiotix S.A.

Via GlobeNewswire

Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris

May 21, 2026

From Nanobiotix S.A.

Via GlobeNewswire

Nanobiotix Announces Launch of Global Follow-On Offering

May 20, 2026

From Nanobiotix S.A.

Via GlobeNewswire

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

May 17, 2026

From Nanobiotix S.A.

Via GlobeNewswire

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study

May 04, 2026

From Nanobiotix S.A.

Via GlobeNewswire

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology

April 20, 2026

From Nanobiotix S.A.

Via GlobeNewswire

Voting Rights and Shares Capital of the Company

April 07, 2026

From Nanobiotix S.A.

Via GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results

March 31, 2026

From Nanobiotix S.A.

Via GlobeNewswire

NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

March 30, 2026

From Nanobiotix S.A.

Via GlobeNewswire

NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026

March 26, 2026

From Nanobiotix S.A.

Via GlobeNewswire

NANOBIOTIX Statement Regarding Recent Media Speculation

March 25, 2026

From Nanobiotix S.A.

Via GlobeNewswire

Voting Rights and Shares Capital of the Company

March 12, 2026

From Nanobiotix S.A.

Via GlobeNewswire

NANOBIOTIX to Participate in Investor Conferences in March

February 25, 2026

From Nanobiotix S.A.

Via GlobeNewswire

Voting Rights and Shares Capital of the Company

February 17, 2026

From Nanobiotix S.A.

Via GlobeNewswire

Voting Rights and Shares Capital of the Company

January 13, 2026

From Nanobiotix S.A.

Via GlobeNewswire

Voting Rights and Shares Capital of the Company

December 17, 2025

From Nanobiotix S.A.

Via GlobeNewswire

NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

December 15, 2025

From Nanobiotix S.A.

Via GlobeNewswire

Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook

November 24, 2025

From Nanobiotix S.A.

Via GlobeNewswire

Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue ↗

November 24, 2025

Via The Motley Fool

Frequently Asked Questions

Is Nanobiotix S.A. - ADSs publicly traded?

Yes, Nanobiotix S.A. - ADSs is publicly traded.

What exchange does Nanobiotix S.A. - ADSs trade on?

Nanobiotix S.A. - ADSs trades on the Nasdaq Stock Market

What is the ticker symbol for Nanobiotix S.A. - ADSs?

The ticker symbol for Nanobiotix S.A. - ADSs is NBTX on the Nasdaq Stock Market

What is the current price of Nanobiotix S.A. - ADSs?

The current price of Nanobiotix S.A. - ADSs is 35.99

When was Nanobiotix S.A. - ADSs last traded?

The last trade of Nanobiotix S.A. - ADSs was at 06/26/26 04:00 PM ET

What is the market capitalization of Nanobiotix S.A. - ADSs?

The market capitalization of Nanobiotix S.A. - ADSs is 1.24B

How many shares of Nanobiotix S.A. - ADSs are outstanding?

Nanobiotix S.A. - ADSs has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.